← Leaderboards
Christina Leigh Stallings
Washington University
$11,157,371
Attributed
$16,667,523
Total exposure
10
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2007–25$2.5M$1.9M$1.3M$625K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,667,523 · 10
By mechanism
R01$14,697,296 · 7
R33$1,395,600 · 1
R21$426,446 · 1
F32$148,181 · 1
Top collaborators
- Eric A Galburt6 shared
- Brian Todd Edelson5 shared
- Fredrik Almqvist4 shared
- Bryan David Bryson2 shared
- Joshua T. Mattila2 shared
- Sudeshna Roy2 shared
Most similar at Washington University
Same institution · by research overlap
- Jeffrey S. Mumm$11,393,203
- Eric A Galburt$5,197,421
- Carl Frieden$6,868,735
- Garland Ross Marshall$5,436,080
- Scott J Hultgren$48,876,558
Others in their field
Top investigators on “Cessation Of Life”
- David R. Weir · University Of Michigan At Ann Arbor$345,522,974
- John M Lachin · George Washington University$134,302,892
- David M Nathan · Massachusetts Institute Of Technology$127,791,564
- Judith S Hochman · New York University School Of Medicine$112,898,313
- Jeffrey H Samet · Boston University Medical Campus$91,739,367
- Judith S. Currier · University Of California Los Angeles$85,330,415
Research focus
Cessation Of LifeMycobacterium TuberculosisTuberculosisInsightIn VivoInfectionPathway InteractionsIn VitroResponsePathogenesisAffectLeadPathogenReportingTuberculosis TreatmentCellsDrug ResistancePhenotypeMycobacterialProductionImmune ResponseMolecularProteinsExperimental Study
Grant awards (35)
Type I IFN-dependent and independent contributions to the outcomes of early innate immune cell interactions during HIV/TB co-infection$872,144
R01 · FY2025 · AI · contact PI
Development of 1,2,4-Triazolyl Compounds and their derivatives as a New Treatment for Tuberculosis$745,546
R01 · FY2025 · AI · contact PI
Targeting NETosis for the Treatment of Tuberculosis$628,284
R01 · FY2025 · AI · contact PI
Type I IFN-dependent and independent contributions to the outcomes of early innate immune cell interactions during HIV/TB co-infection$899,894
R01 · FY2024 · AI · contact PI
Development of 1,2,4-Triazolyl Compounds and their derivatives as a New Treatment for Tuberculosis$787,171
R01 · FY2024 · AI · contact PI
Targeting NETosis for the Treatment of Tuberculosis$628,284
R01 · FY2024 · AI · contact PI
Targeting NETosis for the Treatment of Tuberculosis$629,631
R01 · FY2023 · AI · contact PI
Autophagy proteins in the immune response to Mycobacterium tuberculosis infection$472,998
R01 · FY2023 · AI · contact PI
Regulation of Immune Responses to Mycobacterium tuberculosis Infection$594,246
R01 · FY2022 · AI · contact PI
Autophagy proteins in the immune response to Mycobacterium tuberculosis infection$472,998
R01 · FY2022 · AI · contact PI
Chemical disarming of drug resistance in Mycobacterium tuberculosis$663,411
R01 · FY2021 · AI · contact PI
Regulation of Immune Responses to Mycobacterium tuberculosis Infection$594,246
R01 · FY2021 · AI · contact PI
Autophagy proteins in the immune response to Mycobacterium tuberculosis infection$480,356
R01 · FY2021 · AI · contact PI
Chemical disarming of drug resistance in Mycobacterium tuberculosis$659,913
R01 · FY2020 · AI · contact PI
Regulation of Immune Responses to Mycobacterium tuberculosis Infection$594,246
R01 · FY2020 · AI · contact PI
Autophagy proteins in the immune response to Mycobacterium tuberculosis infection$479,339
R01 · FY2020 · AI · contact PI
Chemical disarming of drug resistance in Mycobacterium tuberculosis$662,129
R01 · FY2019 · AI · contact PI
Regulation of Immune Responses to Mycobacterium tuberculosis Infection$592,674
R01 · FY2019 · AI · contact PI
Autophagy proteins in the immune response to Mycobacterium tuberculosis infection$475,781
R01 · FY2019 · AI · contact PI
Chemical disarming of drug resistance in Mycobacterium tuberculosis$668,717
R01 · FY2018 · AI · contact PI
Regulation of Immune Responses to Mycobacterium tuberculosis Infection$587,643
R01 · FY2018 · AI · contact PI
Targeting a New Essential Virulence Mechanism in Drug-Resistant Mycobacteria$456,360
R33 · FY2018 · AI · contact PI
Targeting a New Essential Virulence Mechanism in Drug-Resistant Mycobacteria$459,801
R33 · FY2017 · AI · contact PI
INVESTIGATING NOVEL MECHANISMS OF TRANSCRIPTION INITIATION REGULATION IN MYCOBACT$288,800
R01 · FY2017 · GM · contact PI
Targeting a New Essential Virulence Mechanism in Drug-Resistant Mycobacteria$479,439
R33 · FY2016 · AI · contact PI
INVESTIGATING NOVEL MECHANISMS OF TRANSCRIPTION INITIATION REGULATION IN MYCOBACT$288,800
R01 · FY2016 · GM · contact PI
INVESTIGATING NOVEL MECHANISMS OF TRANSCRIPTION INITIATION REGULATION IN MYCOBACTERIA$63,645
R01 · FY2016 · GM · contact PI
INVESTIGATING NOVEL MECHANISMS OF TRANSCRIPTION INITIATION REGULATION IN MYCOBACT$288,800
R01 · FY2015 · GM · contact PI
Targeting a New Essential Virulence Mechanism in Drug-Resistant Mycobacteria$204,221
R21 · FY2015 · AI · contact PI
INVESTIGATING NOVEL MECHANISMS OF TRANSCRIPTION INITIATION REGULATION IN MYCOBACT$288,800
R01 · FY2014 · GM · contact PI
Targeting a New Essential Virulence Mechanism in Drug-Resistant Mycobacteria$222,225
R21 · FY2014 · AI · contact PI
INVESTIGATING NOVEL MECHANISMS OF TRANSCRIPTION INITIATION REGULATION IN MYCOBACT$288,800
R01 · FY2013 · GM · contact PI
Mediation of DNA Repair in Mycobacteria by CarD Proteins and ADP-RIbosylation$51,710
F32 · FY2009 · AI · contact PI
Mediation of DNA Repair in Mycobacteria by CarD Proteins and ADP-RIbosylation$49,646
F32 · FY2008 · AI · contact PI
Mediation of DNA Repair in Mycobacteria by CarD Proteins and ADP-RIbosylation$46,825
F32 · FY2007 · AI · contact PI